Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Deloitte
US Department of Justice
Cipla
Julphar
Daiichi Sankyo
Fish and Richardson
UBS
Boehringer Ingelheim

Generated: May 27, 2018

DrugPatentWatch Database Preview

CEFPODOXIME PROXETIL Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Cefpodoxime Proxetil, and when can generic versions of Cefpodoxime Proxetil launch?

Cefpodoxime Proxetil is a drug marketed by Aurobindo Pharma Ltd, Sandoz, Sun Pharm Inds Ltd, Aurobindo Pharma, and Orchid Hlthcare. and is included in seven NDAs.

The generic ingredient in CEFPODOXIME PROXETIL is cefpodoxime proxetil. There are ten drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the cefpodoxime proxetil profile page.
Drug patent expirations by year for CEFPODOXIME PROXETIL
Pharmacology for CEFPODOXIME PROXETIL
Synonyms for CEFPODOXIME PROXETIL
(+-)-1-Hydroxyethyl (+)-(6R,7R)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), isopropyl carbonate (ester)
(6R,7R)-7-[[(2Z)-2-(2-Amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid 1-[[(1-Methylethoxy)carbonyl]oxy]ethyl Ester
(E)-Cefpodoxime Proxetil
(RS)-1-((Isopropoxycarbonyl)oxy)ethyl (+)-(6R,7R)-7-(2-(2-amino-4-thiazolyl)-2-((Z)-methoxyimino)acetamido)-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
(RS)1(isopropoxycarbonyloxy)ethyl (+)-(6R,7R)-7-[2-(2-amino-4-thiazolyl)-2-{(Z)methoxyimino}acetamido]-3methoxymethyl-8-oxo-5-thia-1-azabicyclo [4.2.0]oct-2-ene-2-carboxylate
1-({[(1-methylethyl)oxy]carbonyl}oxy)ethyl (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-[(methyloxy)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
1-(isopropoxycarbonyloxy)ethyl-7-(2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetamido)-3-methoxymethyl-8-oxo-5-thia-1-azabicyclo(4,2,0)-oct-2-ene-2-carboxylate
1-{[(propan-2-yloxy)carbonyl]oxy}ethyl (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
1-{[(propan-2-yloxy)carbonyl]oxy}ethyl 7-{[(2-amino-1,3-thiazol-4-yl)(methoxyimino)acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
1-{[(propan-2-yloxy)carbonyl]oxy}ethyl 7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
1-{[(propan-2-yloxy)carbonyl]oxy}ethyl 7-{[(2Z)-2-(2-imino-2,3-dihydro-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
1-{[(propan-2-yloxy)carbonyl]oxy}ethyl 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-(methoxymethyl)-3,4-didehydrocepham-4-carboxylate
1-isopropoxycarbonyloxyethyl (6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
1-propan-2-yloxycarbonyloxyethyl (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
1-propan-2-yloxycarbonyloxyethyl (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
1-propan-2-yloxycarbonyloxyethyl (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
1-propan-2-yloxycarbonyloxyethyl 7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
1-propan-2-yloxycarbonyloxyethyl 7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
239C814
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(methoxymethyl)-8-oxo-, 1-(((1-methylethoxy)carbonyl)oxy)ethyl ester, (6R-(6alpha,7beta(Z)))-
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(methoxymethyl)-8-oxo-, 1-(((1-methylethoxy)carbonyl)oxy)ethyl ester,(6R-(6-alpha,7-beta(Z)))-
87239-81-4
947692-13-9
AB01209734-01
AB01563099_01
AC1L1E55
AC1L9B34
AC1NS49S
AC1O426I
AC1O6HBL
AK322023
AKOS015994692
AKOS030242963
AN-7622
Antibiotic CS 807
API0001908
Banan
BRD-A87387433-001-01-9
C08115
C21H27N5O9S2
CAS-87239-81-4
CC0150
CCG-100877
CCG-213498
CCG-221250
Cefodox
Cefoprox
cefpodoxime 1-(isopropyloxycarbonyloxy)ethyl ester
Cefpodoxime proxetil (JP17/USP)
Cefpodoxime proxetil [USAN:JAN]
Cefpodoxime proxetil [USAN:USP:JAN]
Cefpodoxime Proxetil EP Impurity D
CEFPODOXIME PROXETIL, VANTIN
Cefpodoximeproxetil
Cefpodoximproxetil
cephalosporin 807
Cephpodoxime Proxetil
Cepodem
CHEBI:3505
CHEBI:94455
CHEMBL1201016
CPD000469193
CS 807
CS-807
CTK7B2648
CTK8F8535
D00920
Doxef
DR003263
DSSTox_CID_2766
DSSTox_GSID_22766
DSSTox_RID_76722
DTXSID1022766
HE399637
HMS2051M14
HMS2093B08
HMS2231C24
HMS3374C02
HMS3393M14
K558
KS-1149
LS-150022
LTINZAODLRIQIX-FBXRGJNPSA-N
MFCD00865088
MLS001401428
MolPort-003-845-692
MolPort-023-220-360
NC00127
NCGC00164598-01
NCGC00183131-01
NSC-759161
NSC759161
Orelox
Otreon
Pharmakon1600-01505637
Podomexef
RU-51807
SAM001246674
SBI-0206821.P001
SCHEMBL27071
SCHEMBL379709
Simplicef
Simplicef [Veterinary]
SMR000469193
SR-05000001937
SR-05000001937-1
STL454343
STL454350
Tox21_113377
Tox21_113428
U 76252
U-76,252
U-76252
Vantin
Xtum-O
ZINC15449381

US Patents and Regulatory Information for CEFPODOXIME PROXETIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma Ltd CEFPODOXIME PROXETIL cefpodoxime proxetil FOR SUSPENSION;ORAL 065409-001 Jun 8, 2007 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Aurobindo Pharma CEFPODOXIME PROXETIL cefpodoxime proxetil TABLET;ORAL 065370-001 Jun 11, 2007 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Sandoz CEFPODOXIME PROXETIL cefpodoxime proxetil FOR SUSPENSION;ORAL 090031-002 Jan 14, 2009 AB RX No Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Sandoz CEFPODOXIME PROXETIL cefpodoxime proxetil TABLET;ORAL 065462-002 May 28, 2008 AB RX No Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Moodys
McKesson
Medtronic
Deloitte
AstraZeneca
McKinsey
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.